Oslo, Norway (12 May 2021 )NattoPharma reports revenues ofNOK 49.9 million for the quarter, a decrease of 11% compared to the same quarter last year. Underlying volumes decreased by 7%. YTD Adjusted EBITDA came in atNOK 11.0 million , equal to a margin of 21.9%. Performance highlights for Q1 2021 (Q1 2020 in brackets) · Operating revenue ofNOK 49.9m (NOK 56.3m ) · Adjusted EBITDA ofNOK 11.0m (NOK 10.5m ) · Adjusted EBITDA margin of 21.9% (18.7%) · Our supply situation, including Natural supply fromIndia , is flowing as normal, with no current delays despite COVID-19 CEO,Kjetil Ramsøy : "The first quarter topline performance is in line with our expectations albeit lower than Q1 2020 which was heavily impacted by both the start of the pandemic last year and a very strong USD. It is gratifying to see that our profitability is at an Adj. EBITDA of nearly 22% in the quarter, creating a solid basis for achieving our full-year guiding. During Q1 we continued to build our inventory position and maintained a strong focus on our working capital to ensure we can meet the growth expectations in 2021." Acquisition byLesaffre On20 April 2021 Lesaffre announced the launch of their mandatory offer onNattoPharma ASA and the offer is expected to conclude onMay 18, 2021 . More information will be available when the mandatory offer has been completed. For more information, please contact:Robert Schrama , CFO,NattoPharma , robert.schrama@nattopharma.com This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.
Click here for more information
© Oslo Bors ASA, source